Director at Connect Biopharma (CNTB) takes shares instead of cash pay

Rhea-AI Filing Summary

Xanthopoulos Kleanthis Gabriel reported acquisition or exercise transactions in this Form 4 filing.

Connect Biopharma Holdings Ltd director Dr. Kleanthis Gabriel Xanthopoulos received a grant of 2,816 ordinary shares on March 31, 2026. These fully vested shares were taken in lieu of a portion of cash compensation for his 2026 annual board retainers for service in the first quarter of 2026. After this award, he directly holds 82,816 ordinary shares of the company.

Insider Trade Summary

Net Buyer: 2,816 shares

Net Buy 1 txn

Insider Xanthopoulos Kleanthis Gabriel

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Ordinary Shares	2,816	$0.00	$0.00

Holdings After Transaction: Ordinary Shares — 82,816 shares (Direct)

Footnotes (1)

1. F1. In accordance with the Connect Biopharma Holdings Limited Non-Employee Director Compensation Program, Dr. Xanthopoulos elected to receive fully vested shares in lieu of a portion of cash compensation for his 2026 annual board retainers. Accordingly, the fully vested ordinary shares were granted to Dr. Xanthopoulos for his service as a director during the first quarter of 2026. The number of shares received in lieu of cash was calculated by dividing the applicable value of the equity by the average closing price of our ordinary shares over the 30 consecutive trading days immediately preceding March 31, 2026, rounded down to the nearest whole share.

Key Figures

Shares granted: 2,816 shares Total shares after grant: 82,816 shares Grant price per share: $0.0000 per share +2 more

5 metrics

Shares granted 2,816 shares Fully vested ordinary shares granted March 31, 2026

Total shares after grant 82,816 shares Direct holdings following the March 31, 2026 transaction

Grant price per share $0.0000 per share Reported transaction price for the 2,816-share grant

Transaction date March 31, 2026 Date of ordinary share grant for board compensation

Averaging period for price 30 trading days Average closing price period used to compute share count

Key Terms

Non-Employee Director Compensation Program, fully vested shares, annual board retainers

3 terms

Non-Employee Director Compensation Program financial

"In accordance with the Connect Biopharma Holdings Limited Non-Employee Director Compensation Program, Dr. Xanthopoulos elected..."

fully vested shares financial

"Dr. Xanthopoulos elected to receive fully vested shares in lieu of a portion of cash compensation..."

annual board retainers financial

"in lieu of a portion of cash compensation for his 2026 annual board retainers."

FAQ

What insider transaction did CNTB report for Dr. Xanthopoulos?

Connect Biopharma reported that director Dr. Kleanthis Gabriel Xanthopoulos received 2,816 fully vested ordinary shares. The award was compensation for his 2026 annual board retainers, specifically for service during the first quarter of 2026, instead of taking that portion in cash.

How many CNTB shares does Dr. Xanthopoulos hold after this grant?

After the March 31, 2026 grant, Dr. Xanthopoulos directly holds 82,816 ordinary shares of Connect Biopharma. This total includes the 2,816 fully vested shares he elected to receive as equity compensation in lieu of a portion of his 2026 annual board retainers.

Was the CNTB insider transaction a purchase or a share grant?

The CNTB insider transaction was a share grant, not an open-market purchase. Dr. Xanthopoulos received 2,816 fully vested ordinary shares at a reported price of $0.0000 per share as non-cash compensation for his 2026 board service in the first quarter.

Why did Dr. Xanthopoulos receive CNTB shares instead of cash?

Under Connect Biopharma’s Non-Employee Director Compensation Program, Dr. Xanthopoulos elected to receive fully vested shares instead of part of his cash retainer. The 2,816 shares represent a portion of his 2026 annual board retainers for first-quarter service, replacing that segment of cash payment.

How was the number of CNTB shares in this grant calculated?

The 2,816 shares were calculated by dividing the applicable equity value by the average closing price of Connect Biopharma’s ordinary shares over the 30 consecutive trading days immediately before March 31, 2026, then rounding the result down to the nearest whole share.

Are the CNTB shares granted to Dr. Xanthopoulos vested?

Yes, the shares granted to Dr. Xanthopoulos are fully vested ordinary shares. They were issued under the Non-Employee Director Compensation Program as immediate equity compensation for his first-quarter 2026 board service, replacing a portion of his scheduled cash board retainers.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 04/02/2026 - 04:27 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Xanthopoulos Kleanthis Gabriel

(Last) (First) (Middle)

3580 CARMEL MOUNTAIN ROAD, SUITE 200

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Connect Biopharma Holdings Ltd [ CNTB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	03/31/2026		A		2,816(1)	A	$0	82,816	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. In accordance with the Connect Biopharma Holdings Limited Non-Employee Director Compensation Program, Dr. Xanthopoulos elected to receive fully vested shares in lieu of a portion of cash compensation for his 2026 annual board retainers. Accordingly, the fully vested ordinary shares were granted to Dr. Xanthopoulos for his service as a director during the first quarter of 2026. The number of shares received in lieu of cash was calculated by dividing the applicable value of the equity by the average closing price of our ordinary shares over the 30 consecutive trading days immediately preceding March 31, 2026, rounded down to the nearest whole share.

Remarks:

	/s/ Lisa Peraza attorney-in-fact for Kleanthis Xanthopoulos	04/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)